|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM309279615 |
| 003 |
DE-627 |
| 005 |
20250227051728.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108428
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1030.xml
|
| 035 |
|
|
|a (DE-627)NLM309279615
|
| 035 |
|
|
|a (NLM)32344017
|
| 035 |
|
|
|a (PII)S1521-6616(19)30553-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Pistillo, Maria Pia
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 29.01.2021
|
| 500 |
|
|
|a Date Revised 29.01.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a The expression of the immune checkpoint molecule CTLA-4 has been almost exclusively studied in the T cell lineage, but increasing evidence has shown its expression on tumors with implications for immunotherapy. To date, the degree of expression of CTLA-4 on tumor cells as a predictive biomarker of response to immune checkpoint inhibitors has not been studied. In this report, we analyzed this issue in melanoma patients treated with CTLA-4 inhibitor Ipilimumab (IPI). We show that the level of CTLA-4 expression on melanoma cells is higher than that on tumor infiltrating lymphocytes (TIL) and it is associated with clinical response to IPI therapy supporting the idea of its possible role as a predictive biomarker
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Best overall response
|
| 650 |
|
4 |
|a CTLA-4
|
| 650 |
|
4 |
|a Immunohistochemistry
|
| 650 |
|
4 |
|a Ipilimumab
|
| 650 |
|
4 |
|a Melanoma
|
| 650 |
|
4 |
|a TIL
|
| 650 |
|
7 |
|a Antineoplastic Agents, Immunological
|2 NLM
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a CTLA-4 Antigen
|2 NLM
|
| 650 |
|
7 |
|a CTLA4 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Ipilimumab
|2 NLM
|
| 700 |
1 |
|
|a Carosio, Roberta
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Grillo, Federica
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fontana, Vincenzo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mastracci, Luca
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Morabito, Anna
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Banelli, Barbara
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tanda, Enrica
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cecchi, Federica
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dozin, Beatrice
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gualco, Marina
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Salvi, Sandra
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Spagnolo, Francesco
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Poggi, Alessandro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Queirolo, Paola
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 215(2020) vom: 01. Juni, Seite 108428
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:215
|g year:2020
|g day:01
|g month:06
|g pages:108428
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108428
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 215
|j 2020
|b 01
|c 06
|h 108428
|